Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  azacitidine
Find trials that include:  Any drugs shown
Results 1-25 of 44 for your search:
Start Over
Azacitidine in Preventing Relapse in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant
Phase: Phase III
Type: Treatment
Age: 18 to 75
Trial IDs: 2008-0503, NCI-2012-01259, NCI-2009-01513, NCT00887068
Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission
Phase: Phase III
Type: Treatment
Age: 55 and over
Trial IDs: CC-486-AML-001, NCI-2013-00084, 2012-003457-28, NCT01757535
A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Age: 18 and over
Trial IDs: 112121, NCI-2014-02104, NCT02158936
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Phase: Phase III
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 2215-CL-0301, NCI-2015-00931, 2015-000140-42, NCT02421939
Azacitidine and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients with Advanced or Metastatic Solid Tumors or Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 19 and over
Trial IDs: HCI53993, NCI-2012-01158, 53993, NCT00748553
Azacitidine and Gemtuzumab Ozogamicin in Treating Patients with Relapsed Acute Myeloid Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 90
Trial IDs: 090516, NCI-2013-01963, Celgene - 090516, NCT00766116
Midostaurin and Azacitidine in Treating Elderly Patients with Acute Myelogenous Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: CASE 1908, NCI-2009-01285, NCT01093573
Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CASE1A09 CC 902, NCI-2010-01139, CASE1A09, NCT01155583
Combination Study of Cytarabine and Tosedostat in Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndromes (MDS)
Phase: Phase II, Phase I
Type: Treatment
Age: 60 and over
Trial IDs: 2011-0188, NCI-2012-01350, NCT01636609
Azacitidine in Treating Patients Undergoing Matched Unrelated Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 201303012, NCI-2012-03105, NCT01747499
Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation in Subjects With Acute Myeloid Leukemia or Myelodysplastic Syndromes
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CC-486-AML-002, NCI-2013-01352, NCT01835587
AC220 With 5-Aza or Low Dose Cytarabine
Phase: Phase II, Phase I
Type: Treatment
Age: Not specified
Trial IDs: 2012-1047, NCI-2013-02274, P50 CA100632, NCT01892371
Oral Rigosertib in Combination With Azacitidine
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Onconova 09-08, NCI-2013-02218, 09-08, 2013-000673-72, NCT01926587
Azacitidine and Romidepsin in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: AAAM3752, NCI-2014-00121, NCT01998035
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 0103-014, NCI-2013-02087, NCT02018926
Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ARO-010, NCI-2015-01403, NCT02400281
Decitabine or Azacitidine in Treating Patients with De Novo or Secondary Myelodysplastic Syndromes
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0507, NCI-2012-02215, NCT01720225
Ruxolitinib Phosphate and Azacytidine in Treating Patients with Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0737, NCI-2013-00704, NCT01787487
Chemotherapy in Treating Patients with Myelodysplastic Syndrome before Donor Stem Cell Transplant
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 2661.00, NCI-2013-00538, 2661, NCT01812252
Azacitidine in Treating Patients with Pancreatic Cancer That Has Been Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J12138, NCI-2013-01406, NA_00076474 / CIR00005424, SKCCC J12138, NCT01845805
Sirolimus and Azacitidine in Treating Patients with High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That Is Relapsed or Refractory or Not Eligible for Intensive Chemotherapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12D.587, NCI-2013-01004, 2012-50, NCT01869114
Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0225, NCI-2013-02252, NCT01893372
Azacitidine and Entinostat Followed by Nivolumab or Nivolumab Alone in Treating Patients with Recurrent Metastatic Non-small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: J1353, NCI-2013-02334, J1353/ NA_00084192, NA_00084192, NA_00084192/CIR00003289, NCT01928576
Start Over